Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$60.91M
• Dividend Yield: N/A
• Average Volume (3M): 43.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: 10.49%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,933,290
• 10 Day Avg. Volume: 31,059
• 30 Day Avg. Volume: 43,967
• PEG Ratio: 0.88
• Price to Book (P/B): -21.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.79 ▼(-42.63% Downside)

The score is primarily held down by weak financial performance (zero latest revenue, persistent losses and cash burn, and negative equity) and bearish technicals (price below key moving averages with negative MACD). Valuation provides only limited offset because the company is loss-making and offers no dividend yield.

Positive Factors

Focused therapeutic platform

Arch’s concentrated DPEP-1 inhibitor platform and complementary monoclonal antibody program create a coherent R&D focus that can be applied across multiple acute and inflammatory indications. That platform-centric model supports scientific leverage, repeatable development pathways, and clearer partnering conversations over months to years, increasing long-term optionality vs a one-off asset approach.

Partnering/licensing business model

The company’s explicit go-to-market model—out-licensing and partnerships plus equity raises—is durable for clinical-stage biotech. It limits the need for large commercial infrastructure, offers milestone and royalty upside if assets succeed, and aligns incentives with larger pharma partners, giving clear, sustainable routes to monetize clinical progress over the medium term.

Improving cash burn trend

Reported improvement in cash burn in 2025 versus 2024 suggests better expense control or program prioritization. While still cash flow negative, a downward trend in burn rate is a constructive durable signal: it extends runway, reduces near-term financing frequency, and improves prospects for reaching partnership-enabling milestones without immediate dilution.

Negative Factors

Stressed balance sheet

Negative shareholders’ equity and a very small asset base are fundamental solvency concerns. Debt levels (historically ~$2.8–$5.2M) versus minimal assets limit financial flexibility, raise refinancing and covenant risk, and structurally increase the chance management must secure dilutive financing or aggressive licensing terms to sustain operations over the coming months.

Persistent negative cash generation

Consistent operating and free cash flow deficits indicate the company is not self-sustaining and relies on external funding. Even with some burn improvement, ongoing negative cash generation forces recurring fundraising or licensing, which can dilute shareholders or compress deal economics and represents a durable execution risk for advancing clinical programs.

Volatile and absent recent revenue

Highly inconsistent revenue and a drop to zero in the latest period reveal limited visibility into sustainable non-dilutive income such as licensing. This undermines funding predictability and the company’s ability to support multi-year clinical programs without material external financing, making long-term development planning more fragile.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

How the Company Makes Money

Arch Biopartners primarily generates revenue through the development and commercialization of its drug candidates. The company invests in the research and development of its proprietary technologies, aiming to bring them to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams include potential licensing agreements, milestone payments, and royalties from successful commercialization of its drug candidates. Additionally, Arch Biopartners may receive government grants or research funding to support its development efforts, particularly for projects addressing unmet medical needs.

Arch Biopartners Financial Statement Overview

Summary

Financial strength is weak: revenue is highly inconsistent and fell to zero in the latest period, losses persist, and cash flow remains negative. The balance sheet is particularly stressed with negative shareholders’ equity and a very small asset base, increasing funding and solvency risk despite some improvement in losses/cash burn.

Income Statement

Operating performance remains weak. Revenue has been highly volatile, rising sharply in 2021 and 2023–2024, but falling to zero in 2025, suggesting limited visibility and inconsistent commercialization/partnering income. Profitability is structurally negative: gross profit is negative in most years and operating losses persist every year, with net losses still sizeable in 2025 despite lower losses than 2024. Overall, the trajectory reflects a company still in heavy investment mode with limited and unstable revenue support.

Balance Sheet

The balance sheet is stressed. Shareholders’ equity is negative across all periods, which is a key solvency red flag and indicates the capital structure is impaired. Debt remains meaningful (roughly $2.8–$5.2M historically) relative to a very small asset base (down to ~$0.1M in 2025), limiting flexibility and increasing refinancing/financing risk. While debt has come down from 2021–2023 levels, negative equity and shrinking assets keep financial risk elevated.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow below zero every year, indicating ongoing cash burn. Cash burn did improve in 2025 versus 2024, but free cash flow still declined year over year in 2025 and remains meaningfully negative, implying continued reliance on external funding. A relative positive is that cash flow losses broadly track accounting losses (free cash flow is roughly in line with net loss), but the absolute level of burn remains a key concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	2.12M	1.98M	964.68K	3.89M
Gross Profit	0.00	0.00	-1.66M	-129.00K	-503.00K	-150.00K
EBITDA	-1.29M	-1.29M	-3.53M	-336.00K	-101.00K	-77.02K
Net Income	-1.55M	-1.55M	-3.92M	-3.33M	-1.41M	-1.17M
Balance Sheet
Total Assets	104.53K	104.53K	935.62K	1.17M	621.64K	2.67M
Cash, Cash Equivalents and Short-Term Investments	2.10K	2.10K	2.97K	831.27K	506.35K	448.24K
Total Debt	2.84M	2.84M	2.77M	5.02M	4.41M	5.16M
Total Liabilities	3.99M	3.99M	5.28M	6.68M	5.09M	6.55M
Stockholders Equity	-3.88M	-3.88M	-4.35M	-5.51M	-4.47M	-3.88M
Cash Flow
Free Cash Flow	-1.58M	-1.58M	-2.33M	-234.08K	-1.08M	-2.98M
Operating Cash Flow	-1.58M	-1.58M	-2.33M	-234.07K	-1.08M	-2.98M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.58M	1.58M	1.50M	559.00K	-421.37K	2.78M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.22, and below the 200-day MA of 1.46, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 28.77 is Positive, neither overbought nor oversold. The STOCH value of 24.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	$258.01M	-7.35	-89.10%	―	―	27.53%
ARCH	44 Neutral	C$60.91M	-34.18	―	―	―	10.49%
MDNA	44 Neutral	C$59.11M	-4.83	-91.21%	―	―	54.74%
BCT	44 Neutral	C$35.28M	-0.08	-409.25%	―	―	62.01%